12:00 AM
 | 
Jul 13, 1998
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AnergiX: ANRG began Phase I testing

Anergen Inc. (ANRG), Redwood City, Calif.
Product: AnergiX peptide from cartilage-derived glycoprotein HCgp39
Indication: Treat rheumatoid arthritis
Status: ANRG...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >